The panel’s vote follows data showing patients with unresectable or metastatic esophageal squamous cell carcinoma and HER2-negative, microsatellite stable gastric/gastroesophageal adenocarcinoma who have a PD-L1 expression of less than 1% experience the risks of immunotherapy without the benefits.
Requiring a PD-L1 of 1% or higher for the immunotherapies would align FDA guidance with guidelines from the American Society of Clinical Oncology and the National Comprehensive Cancer Network.
The requirement would also apply to the immune checkpoint inhibitor tislelizumab, according to the Medscape report.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
